Published in Law and Health Weekly, September 15th, 2007
This research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the chemotherapy and targeted therapies markets. Targeted Therapy Improves Survival Rates among Patients with Head and Neck Cancer.
Physicians in Europe are eager for novel therapies for head and neck cancer, as five-year survival rates among patients have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.